ABSTRACT
Introduction

47
Rhodococcus equi, previously known as Corynebacterium equi, is a facultative intracellular,
48
Gram-positive coccobacillus that causes infection in a wide variety of animal species and 49 humans. Rhodococcosis occurs preferentially in organisms whose immune systems are 50 compromised, either naturally, or due to illness or medical treatment (21).
51
The infection is typically described in one to six month-old foals (41, 46) and is one of the 52 most common causes of mortality at this age. The high susceptibility of foals to the pathogen 53 is due to their immature immune system combined with the decrease in maternal specific of rhodococcosis cases, R. equi was solely responsible for lethal lesions. In the other 40%, R. 63 equi was found in co-infection with another pathogen, mainly Klebsiella pneumoniae in lung 64 lesions (24.3%) and Streptococcus zooepidemicus (9.3%) which can sometimes cause the 65 treatment to fail, due to the difference in antibiotic sensitivity (30, 32) . Combinations of such 66 pathogens have already been described previously (30).
67
In humans, the infection is rare in immunocompetent patients (15, 28) but more than 300 68 cases have been reported in immunocompromised subjects (42, 47) . Since the first human 
81
It is a cause for concern that the susceptibility of bacteria to rifampin and erythromycin tends 82 to decrease over time. Buckley et al. highlighted a two-fold increase in minimum inhibitory 83 concentrations (MICs) over a ten-year period (10) . Moreover, the emergence of rhodococci 84 resistant to these antibiotics has already been reported in humans and animals (2, 7, 10, 29).
85
This suggests that there may be a problem in the treatment of R. equi infection and new 86 effective broad-spectrum drugs will be needed in the near future. Antimicrobial peptides 
100
The aim of the present study was to evaluate the in vitro potential of these two equine 101 antimicrobial peptides for the treatment of rhodococcosis, and the effect on its associated 102 pathogens.
104
Materials and methods
105
Antibiotics and antimicrobial peptides 106 The antimicrobial peptide eCATH1 was chemically synthesized by GenScript USA Inc. 
Salt tolerance
154
Salt tolerance of eCATH1 was determined using the microdilution assay as described The FIC indexes were interpreted as follows: <0.5, synergy; 0.5 to 4.0, indifferent; and >4.0,
198
antagonism (1). In some cases, the interpretation may vary (6), therefore, a second method 199 ("two-well") was used for confirmation. The two-well method defined synergy as the absence 200 of turbidity in the two wells containing 0.25 x MIC of both drugs and 2 x MIC of both drugs.
201
Antagonism was defined as the presence of turbidity in both of these wells, whereas
202
indifference was defined as all other possibilities (16). 
Results
247
Circular dichroism spectroscopy (CD)
248
In the absence of liposomes, DEFA1 had a CD-spectrum whose maximum was at 230 nm 249 which is typical for proteins with a β-sheet structure (Fig. 1 
273
In the absence of sodium chloride, eCATH1 was able to kill 90% of R. equi ATCC 33701 P+ 274 at 2.2 µg/ml (LD90) and 99.9 % (MBC) at 4.4 µg/ml (Fig. 2) . The MBC and the MIC values were similar, indicating that eCATH1 has a bactericidal rather than bacteriostatic effect on R.
276
equi. In the presence of 50 mM of sodium chloride, the LD90 was twice as high but the MBC 277 remained at 4.4 µg/ml. At a physiological salt concentration (150 mM), eCATH1 maintained 278 its relatively high killing activity, since the MBC was only increased by a factor of two (8.8 279 µg/ml) compared with the no-salt conditions (Fig. 2) .
280
The antibacterial activity of eCATH1 in combination with DEFA1 or an antibiotic (rifampin, 281 erythromycin) against R. equi P103 P-is shown in Table 2 . Interestingly, there was synergy 282 when eCATH1 was combined with the RNA polymerase inhibitor rifampin (FIC < 0.5).
283
However, this peptide was indifferent in combination with DEFA1 or erythromycin (0.5 <
284
FIC ≥ 4). All these data were confirmed by the "Two-well" method (data not shown). numerous cellular fragments could be observed after treatment indicating cellular lysis (Fig.   295 3).
297
Cytotoxicity of the antimicrobial peptides
298
The cytotoxicity of eCATH1 and DEFA1 was assessed by the LDH release assay using RK13
299
and VERO epithelial cells and a maximum of 100 µg/ml of peptide (Fig. 4) . For both cell 300 lines, eCATH1 did not significantly affect plasma membrane integrity of cells. Compared to 301 the negative control, no cytotoxicity was observed up to 50 µg/ml and only minor cytotoxicity 302 (10%) was observed for the VERO cell line at 100 µg/ml (Fig. 4A) . The RK13 cells were 303 unaffected by 100 µg/ml of eCATH1 (Fig. 4B) . In contrast, DEFA1 was found to be more 304 cytotoxic, with a substantial effect on VERO cells at 50 µg/ml. At 100 µg/ml of DEFA1, the 305 membrane integrity of RK13 and VERO cells was strongly affected (Fig. 4A & B) . In 306 addition, eCATH1 and DEFA1 were tested for hemolytic activity against sheep and horse 307 erythrocytes. For both peptides no significant hemolytic activity (< 3%) was observed up to 308 100 µg/ml (data not shown). and hydrophobic antibiotics (reviewed in (11)) and it was hypothesized that AMPs allow the 363 antibiotic to access its intracellular target by permeabilization of the bacterial membrane.
364
Therefore, AMPs represent a way of enhancing the activity of classical antibiotics but even 365 more they could potentially tackle the problem of the rise in multidrug-resistant pathogens.
366
Both, DEFA1 and eCATH1 interacted with liposomal membranes that have a net negative 367 surface charge. In contrast, there was no interaction with liposomes with a neutral surface.
368
Furthermore, the tested liposomes were free of any membrane proteins. Therefore, the values, and cytotoxicity of both peptides.
379
In conclusion, the in vitro therapeutic potential of equine DEFA1 for rhodococcosis treatment 380 was found to be lower than envisaged mainly due to its cytotoxicity but also to its inefficacy 
